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SUMMARY : The effects of intravenous diltiazem on supraventricular tachy-
arrhythmias were studied in 16 patients : 6 with paroxysmal supraventricular tachycardia 
using an accessory pathway retrogradely, 6 with atrial fibrillation, 3 with atrial flutter 
and 1 with chronic atrial tachycardia. Diltiazem (0.1 or 0.2 mg/kg) was administered 
intravenously over 5 minutes. 
   Termination of paroxysmal supraventricular tachycardia was achieved in 6 out of 
10 episodes during or just after the injection. Diltiazem slowed the ventricular conduction 
from 2 : 1 to 4 : 1 in atrial flutter, but sinus rhythm was not restored in either case. Diltiazem 
increased the ventricular response through an accessory pathway in a patient with atrial 
fibrillation associated with Wolff-Parkinson-White syndrome. Atrial rate in a case of 
chronic atrial tachycardia did not change significantly. There were no adverse clinical 
effects. 
   It is concluded that diltiazem is effective in slowing ventricular rate in atrial fibrilla-
tion and flutter and in terminating paroxysmal supraventricular tachycardia. However, 
diltiazem may be contraindicated in atrial fibrillation associated with Wolff-Parkinson-
White syndrome.
       INTRODUCTION 
 Diltiazem, a 1, 5-benzothiazepine derivative, 
is one of the compounds blocking the inward 
flux of calcium during cellular depolarization''. 
Diltiazem, originally introduced for the treat-
ment of angina pectoris", has been shown to 
have antiarrhythmic properties"". However, 
there are a few detailed reports about the effects 
of intravenous diltiazem on supraventricular 
tachyarrhythmias4-8' 
   In this report we present the effects of 
intravenous diltiazem on various types of su-
praventricular tachyarrhythmias.
    SUBJECTS AND METHODS 
 Study patients : Diltiazem was administered 
intravenously to 16 patients with supraventric-
ular tachyarrhythmias on 22 occasions. The 
clinical features of the patients are summarized 
in Tables 1 and 2. The patients were divided 
into four groups according to the type of su-
praventricular arrhythmias. 
 Group A was composed of 6 patients with 10 
spontaneous episodes of paroxysmal supraven-
tricular tachycardia using the atrioventricular 
node antegradely and an accessory pathway 
retrogradely, which was demonstrated at elec-
trophysiological study (4 with manifest Wolff-
Parkinson-White syndrome and 2 with conceal-
ed Wolff-Parkinson-White syndrome). 
 Group B consisted of a patient with chronic 
atrial tachycardia (repetitive type). Diltiazem 
was administered on 2 separate occasions to this 
patient. 
 Group C consisted of 3 patients with 3 epi-
sodes of atrial flutter. 
 Group D included 6 patients with atrial fi-
brillation (5 with paroxysmal and 1 with chron-
ic atrial fibrillation). 
 Intravenous administration of diltiazem : In-
formed consent was obtained from all patients 
for the administration of diltiazem intravenous-
ly. All patients received a bolus injection of 
diltiazem at a dose of 0.1 mg/kg (4 occasions) 
or 0.2 mg/kg (18 occasions), administered by 
hand infusion over 5 minutes. When supra-
ventricular tachyarrhythmias were converted to 
normal sinus ryhthm during the injection, the 
bolus injection was stopped immediately. 
 Continuous electrocardiographic monitoring 
and direct slow speed recording were performed 
during diltiazem administration and continued 
3 hours after the injection. 
 Blood pressure was measured immediately 
before the injection of diltiazem and at 1, 3, 5, 
10, 15, 30, 60, 120 and 180 minutes afterwards. 
 Blood samples were drawn for plasma dil-
tiazem measurements just before the adminis-
tration and at 5, 15, 30, 60, 120, 180 and 240 
minutes after the beginning of the injection. 
Diltiazem plasma concentration was measured 
by a gas chromatographic method". 
 Statistical analysis : Differences in heart rate 
and blood pressure measured before and after 
diltiazem administration were analyzed for sig-
        Table 1. Clinical Features of Patients and Response to Diltiazem (Group A and B) 
    Patient Age (years) Cardiac Dose Response to                 & 
sex Diagnosis mg/kg (Total) diltiazem 
 Group A (Paroxysmal Supraventricular Tachycardia associated with WPW) 
     1A 44M Normal 0.1 (5.0) Slowed 
                           Manifest WPW (190/min -- 110/min) 
     lB 0.2 (10.0) Slowed 
                                                               (155/min -- 97/min)
     2A 18M Normal 0.2 (6.7) Terminated 
                           Concealed WPW *(165 sec) 
     2B 0.2 (13.4) Terminated 
                                                             *(360 sec) 
     2C 0.2 (10.2) Terminated 
                                                             *(240 sec) 
     3A 61M Normal 0.2 (4.0) Terminated 
                          Manifest WPW *(90 sec) 
     3B 0.2 (10.6) Terminated 
                                                             *(240 sec) 
     4 14M Normal 0.2 (8.0) Terminated 
                          Manifest WPW *(200 sec) 
     5 11F Normal 0.2 (7.0) Slowed
                           Operated (170/min - 140/min) 
                           Concealed WPW 
                 56F Normal 0.2 (12.2) Slowed 
     6 Manifest WPW (168/min -152/min) 
 Group B (Chronic Atrial Tachycardia) 
     7A 21F Normal 0.1 (4.3) ectopic P-R interval 
                                                                    0.19 sec to 0.24 sec. 
     7B 0.2 (8.6) ectopic P-R interval 
                                                                    0.21 sec to 0.24 sec. 
*Time elapsing from the beginning of diltiazem injection to termination of supraventricular tachycardia . 
Abbreviatiion : WPW = Wolff-Parkinson-White Syndrome.
        Table 2. Clinical Features of Patients and Response to Diltiazem (Group C and D) 
                                                 Mean Heart           Age 
Cardiac Dose Rate Previous 
 t atient (years) Di
agnosis mg/kg (beats min) Response to Diltiazem therapy          & 
sex (Total) C ° =D 
 Group C (Atrial Flutter) 
  8 69F Normal 0.2 (8.4) 155 98 Ventricular rate 
                                                      decreased ; 
                                                  atrial flutter 2: 1 
                                                    mostly 4: 1 
  9 49M PS associated 0.2 (9.8) 144 80 Ventricular rate Methyldigoxin 
               with ASD decreased ; 0.1 mg 
                                                  atrial flutter 2: 1 
                                                    mostly 4: 1 
  10 66M MS, AR 0.1 (5.5) 146 81 Ventricular rate Lanatoside 
                                                        decreased ; C 0.4 mg i. V. 
                                                  atrial flutter 2: 1 3 hours before
                                                    mostly 4: 1 
                                                        conversion to atrial
                                                fibrillation at 
                                                  15 minutes 
 Group D (Atrial Fibrillation) 
  11 51F Normal, 0.2 (11.0) 162 142 
                Paroxysmal AF 
  12 59M IHD, 0.2 (9.8) 72 53 
              Chronic AF 
  13 52M OMI, 0.2 (11.4) 79 54 Ventricular rate 
                Paroxysmal AF decreased 
  14 57M Normal, 0.2 (13.0) 99 67 
                Paroxysmal AF 
  15 41M HOCM, 0.1 (4.6) 117 80 
                Paroxysmal AF 
  16A 44M Normal, 0.2 (12.4) 118 83 Ventricular rate Procainamide 
                Paroxysmal AF decreased ; 520 mg i. V. 
                associated A-V conduction 30 minutes
               with WPW slowed ; Accessory before.
                                                    pathway conduction 
                                                         unchanged
  16B 0.2 (12.4) 119 73 Ventricular rate 
                                                      decreased ; 
                                                      A-V conduction
                                                        slowed, but Accessory 
                                                    pathway conduction
                                                         unchanged
'Minimal ventricular rate within 30 minutes of diltiazem adiministration . 
Abbreviations : AF = atrial fibrillation, AR = aortic regurgitation, ASD = atrial septal defect, C = control, 
D = diltiazem, HOCM = hypertrophic obstructive cardiomyopathy, IHD = ischemic heart disease, MS = 
mitral stenosis, OMI = old myocardial infarction, PS = pulmonary stenosis, WPW = Wolff-Parkinson-White 
syndrome.
nificance using a t test. A p value of 0.05 or 
less was considered statistically significant. 
 Definitions : Participation of an accessory 
atrioventricular pathway during supraventric-
ular tachycardia and the diagnosis of chronic
atrial tachycardia were established using cri-
teria described previously1o-12. 
 Ventricular rate during atrial fibrillation and 
atrial flutter, and atrial rate of chronic atrial 
tachycardia was determined by averaging over 
60 seconds.
          RESULTS 
 Group A - Paroxysmal Supraventricular 
Tachycardia Associated with Wolff-Parkinson-
White Syndrome. 
 Four patients had left lateral accessory path-
ways that conducted bidirectionally and two 
patients had concealed left lateral accessory 
pathways. In all patients, the conduction during 
supraventricular tachycardia proceeded ante-
gradely in the atrioventricular node and retro-
gradely in the accessory pathway. 
 Diltiazem was administered on 10 spontane-
ous episodes to the 6 patients with paroxys-
mal supraventricular tachycardia. The drug 
was injected twice or 3 times in Patients 1, 2 
and 3 (Table 1), for episodes of supra-
ventricular tachycardia occurring on different 
days.
 A bolus injection of 0.2 mg/kg was adminis-
tered 9 times in 6 patients with paroxysmal 
supraventricular tachycardia. Supraventricular 
tachycardia terminated after a bolus injection 
in 3 patients (6 times in total), whereas the ven-
tricular rate decreased after the injection in the 
remaining 3 patients (3 times in total). 
 Fig. 1 shows the change in the ventricular rate 
of paroxysmal supraventricular tachycardia in 
6 episodes of 3 cases which terminated after the 
injection of 0.2 mg/kg. The ventricular rate 
began to decrease gradually during the injection 
(169±32/min (mean±standard deviation) to 155± 
24/min) and conversion to sinus rhythm was 
achieved after a mean interval of 3.6±1.5 mi-
nutes from the onset of the injection. 
 Fig. 2 shows the change of the ventricular rate 
after intravenous diltiazem of 0.1 or 0.2 mg/kg 
in the remaining 3 cases of paroxysmal supra-
ventricular tachycardia which did not termi-
Fig. 1. The change in the ventricular rate of 
       paroxysmal supraventricular tachycardia
      (PSVT) in 3 patients (6 episodes) which ter-
      minated after the injection of diltiazem (0.2 
      mg/kg). Unfilled circles indicate supraven-
      tricular tachycardia and the filled circles 
      sinus rhythm.
Fig. 2. The ventricular rate after intravenoous 
      diltiazem of 0.1 or 0.2 mg/kg in the 3 cases 
      of paroxysmal supraventricular tachycardia 
      which did not terminate, but slowed. In the 
      case shown with the broken line (Case 1-A), 
       the ventricular rate was markedly decreased
      by diltiazem even at a dose of 0.1 mg/kg.
nate, but slowed. 
 In Patient 1, diltiazem was administered in 
two dosages : 0.1 and 0.2 mg/kg. The ventricular 
rate before the injection changed markedly 
within a short time (170/min to 190/min) (Fig. 
2, Pt 1-A). 
 Initially 0.1 mg/kg was administered and the 
ventricular rate decreased from 190/min to 110/ 
min 15 minutes after the injection. However, 
supraventricular tachycardia did not terminate 
and 0.2 mg/kg was administered 4 hours later 
(Fig. 2, Pt 1-B). The ventricular rate decreased 
further, from 115/min to 97/min, 15 minutes after 
the injection. Although supraventricular tachy-
cardia did not terminate spontaneously, it could 
be terminated easily by a Valsalva maneuver 
done 30 minutes after the injection of 0.2 mg/ 
kg.
Group B - Chronic Atrial Tachycardia. 
 Diltiazem at doses of 0.1 and 0.2 mg/kg was 
administered on different days in a case with 
chronic atrial tachycardia of repetitive type 
(Table 1). The atrial rate (139/min) remained 
unchanged 15 minutes after the injection of 0.1 
mg,/kg. However, P-R interval prolonged from 
0.19 second to 0.24 second. The atrial rate 
failed to slow even after a further injection of 
0.2 mg/kg, despite P-R interval prolongation. 
Group C Atrial Flutter. 
 Patient 10 received 0.1 mg/kg of diltiazem, and 
Patients 8 and 9 received 0.2 mg/kg (Table 2). 
Both doses slowed the ventricular rate mar-
kedly 15 to 30 minutes after the injection and 
atrioventricular conduction changed from 2 : 1 
to 4: 1. However, there was no significant
Fig. 3. The change in the mean ventricular rate of 
      atrial flutter after intravenous diltiazem.
      The broken line indicates 0.1 mg/kg and 
      the solid lines 0.2 mg/kg. At both doses the 
      ventricular rate decreased markedly 15 to
      30 minutes after the injection and the atrio-
      ventricular conduction changed from 2: 1 
      to 4: 1. The ventricular rate began to in-
      crease gradually 1 hour after the injection, 
      but the effect of the drug continued for a 
      total of 3 hours.
Fig. 4. The change in mean ventricular rate of 
      atrial fibrillation after injection of diltiazem. 
       The mean ventricular rate decreased 
      makedly 15 to 30 minutes after the injection 
      and the effect of the drug continued for up 
      to 3 hours in four of five cases.
change in the F-F rate. The ventricular rate 
began to increase gradually one hour after the 
injection, taking a mean of 3 hours to return 
to the pretreatment value (Fig. 3). 
 None of the cases with atrial flutter was 
converted to sinus rhythm. 
 Intravenous lanatoside C, 0.4 mg, was in-
effective in Patient 10. Diltiazem (0.1 mg/kg) 
given 3 hours after the lanatoside C slowed the 
ventricular rate from 146/min to 81/min 15 
minutes after the injection and thereafter atrial 
flutter converted to atrial fibrillation. The 
ventricular rate was controlled at about 80/min 
despite atrial fibrillation for a duration of 60 
minutes following the injection. 
Group D - Atrial Fibrillation. 
 Five patients had paroxysmal atrial fibrilla-
tion and one was in chronic atrial fibrilla-
tion. The drug was given intravenously at 0.1 
mg/kg to one patient and at 0.2 mg/kg to the 
remaining 5 patients (Table 2 and Fig. 4). 
 The ventricular rate of Patient 11 decreased 
from 162/min to 142/min just after the injection 
of 0.2 mg/kg, but it began to increase thereafter. 
In Patients 12, 13 and 14 the ventricular rate also 
decreased from 83±14/min to 61±5/min 15 
minutes after the injection of 0.2 mg/kg and this 
ventricular rate was maintained for 60 minutes. 
Three hours after the injection the mean 
ventricular rate was still slowed at 66±15/min. 
In Patient 11 the ventricular rate did not de-
crease satisfactorily. Diltiazem was adminis-
tered 30 minutes after the onset of atrial fibrilla-
tion in Patient 11 and 2 days after the onset in 
Patients 13 and 14. 
 Patient 15 had hypertrophic obstructive car-
diomyopathy complicated by atrial fibrilla-
tion. Diltiazem, 0.1 mg/kg, was injected intra-
venously over 10 minutes in this case 24 hours 
after the onset of atrial fibrillation. The ven-
tricular rate decreased from 117/min to 80/min 
30 minutes after the injection. The effect of the 
drug could still be seen after 3 hours. 
Group D Atrial Fibrillation Associated with 
Wolff-Parkinson-White Syndrome. 
 Patient 16 suffered from paroxysmal atrial 
fibrillation associated with Wolff-Parkinson-
White syndrome (Figs. 5 and 6). The QRS
Fig. 5. (A)
                 Fig. 5. (B) 
Fig. 5. Case 16-A. (A) Ventricular response in atrial 
      fibrillation associated with Wolff-Parkin-
      son-White syndrome after the injection of 
      procainamide plus diltiazem. (B) Tracings
      were recorded before and 20 minutes after 
      procainamide administration and before 
      and 15, 60, and 120 minutes after diltiazem 
      administration. See text for details.
during atrial fibrillation in this case was mostly 
narrow (mainly conducted through the a.trio-
ventricular node) and occasionally wide (ex-
clusively conducted through the accessory 
pathway). Procainamide was given prior to 
diltiazem at the onset of atrial fibrillation (Fig. 
5A and B). The systolic pressure fell from 125 
mmHg to 92 mmHg after the injection of 
procainamide (500 mg) given over 10 minutes. 
The injection of procainamide was therefore 
discontinued. The rate of narrow QRS com-
plexes slightly decreased and the incidence of 
wide QRS complexes decreased from 20/min to 
2-4/min after the injection of procainamide. 
With intravenous diltiazem (0.2 mg/kg) admin-
istered about 20 minutes later, the rate of narrow 
QRS complexes decreased from 118/min to 83/ 
min over 15 minutes. However, the incidence 
of wide QRS complexes remained unchanged.
 The response of atrial fibrillation to dil-
tiazem (0.2 mg/kg) without prior administration 
of procainamide was observed on another day 
(Fig. 6A and B). The narrow QRS complex rate 
decreased from 104/min to 68/min 15 minutes 
after the injection of diltiazem. However, the 
incidence of wide QRS complexes began to 
increase gradually 15 minutes after the injection, 
resulting in frequent responses of 40 to 50 
complexes/min 2 hours later. After 3 hours the 
incidence of wide QRS complexes had returned 
to baseline. Supraventricular tachycardia of 4 
minutes' duration occurred transiently 4 hours 
later, but it reverted to sinus rhythm sponta-
neously. 
 Blood pressure : After the injection of 0.2 mg/ 
kg in 9 patients without paroxysmal supraven-
tricular tachycardia, the systolic blood pressure 
fell from 108±16 to 97±12 mmHg, and the
                Fig. 6. (A) Fig. 6. (B) 
Fig. 6. Case 16-B. (A) Ventricular response in atrial fibrillation associated with Wolff-Parkinson-White 
      syndrome after the injection of diltiazem without the preinjection of procainamide. (B) Tracings 
      were recorded before and 10, 30, 60, 120, 180, 240 and 244 minutes after the injection of diltiazem. 
      See text for details.
Fig. 7. The time course of the plasma concentra-
      tion of diltiazem after the injection of 0.1 
      mg/kg (shown broken line) in 3 and of 0.2
      mg/kg (shown solid line) in 9 patients. See
        text fnr rletnilc
diastolic blood pressure fell from 68±18 to 62± 
9 mmHg. This reduction in blood pressure did 
not reach statistical significance. 
 Diltiazem Plasma Concentration : Fig. 7 shows 
the time course of the mean plasma concen-
tration of diltiazem after the injection of 0.1 mg/ 
kg (5.3±0.2 mg in total) in 3 and of 0.2 mg/kg 
(10.8±1.7 mg in total) in 9 patients. The mean 
plasma concentration following 0.2 mg/kg 
decreased rapidly from 377±160 to 62±22 ng/ml 
within 30 minutes of the injection. Thereafter 
it decreased slowly reaching a mean value of 
18±12 ng/ml afer 3 hours. The elimination 
half-life of intravenous diltiazem (0.2 mg/kg) 
calculated from this curve by a 2 compartment 
open model was 1.93 hours. 
 No complications or unwanted effects were 
observed after the injection of diltiazem. 
         DISCUSSION 
 Animal experimental observations suggest : 
(1) that atrioventricular nodal cells are slow-
channel-dependent, (2) that atrioventricular 
nodal conduction can be slowed or blocked by 
agents that interfere with slow inward current
and (3) that the refractory period is also pro-
longed by such agents"' 14'. Verapamil exerts 
such an action and is used extensively as an 
antiarrhythmic agent for supraventricular 
tachyarrhythmiasl4- 17'. 
 Diltiazem is a widely used antianginal drug 
in Japan",") and is finding a place in anti-
anginal treatment in Europe" 21) Recent electro-
physiological studies indicate that diltiazem 
inhibits atrioventricular conduction and is ef-
fective against supraventricular arrhythmias2' 3'. 
However, few detailed prospective studies of 
intravenous diltiazem on supraventricular tachy-
arrhythmias have ever been reported'`"''. 
 In this study we prospectively studied the 
effect of intravenous diltiazem on various types 
of supraventricular arrhythmias and also ob-
served the safety of this drug in patients with 
underlying cardiac disease. The drug was well 
tolerated on all occasions by all subjects. 
Effects on Paroxysmal Supraventricular Tachy-
cardia Associated with Wolff-Parkinson-White 
Syndrome. 
 Diltiazem, 0.2mg/kg, was administered intra-
venouly in 6 patients with 9 episodes of paroxys-
mal supraventricular tachycardia. Supraventri-
cular tachycardia terminated in 3 patients (6 
episodes). The ventricular rate slowed in the 
remaining 3 patients without termination of 
supraventricular tachycardia. It seems likely 
that these effects of diltiazem are due to 
inhibition of antegrade atrioventricular nodal 
conduction2 5' 
Effects on Atrial Flutter and Atrial Fibrillation. 
 The atrioventricular conduction in atrial 
flutter was depressed by diltiazem with altera-
tion from 2: 1 to 4: 1 conduction, resulting in 
reduction of ventricular rate. However, no 
change in F-F rate occurred. 
 The ventricular rate of atrial fibrillation was 
slowed maximally at 15-30 minutes after the 
injection of diltiazem. The effect of diltiazem 
persisted for 3 hours. In Patient 11, there was 
only a slight decrease in the ventricular rate. 
Diltiazem had been administered only 30 min-
utes after the onset of atrial fibrillation in this 
case, unlike the other cases. It may be that the 
effect of diltiazem was weakened by increased
sympathetic tone due to the acute onset of atrial 
fibrillation. 
 Atrial fibrillation and atrial flutter did not 
convert to sinus rhythm after intravenous 
injection of 0.2 mg/kg of diltiazem, but the drug 
was found to be effective for controlling the 
ventricular rate. 
Effect of Atrial Fibrillation Associated with 
Wolff-Parkinson-White Syndrome. 
 Patient 16 was in atrial fibrillation associat-
ed with Wolff-Parkinson-White syndrome. Fol-
lowing intravenous diltiazem the ventricular 
response through the atrioventricular node 
decreased, but there was a marked increase in 
conduction via the accessory pathway. When 
procainamide was administered prior to dil-
tiazem, the ventricular response through the 
accessory pathway did not increase after the 
injection of diltiazem. An increase in the ven-
tricular response through the accessory path-
way is also seen after the injection of vera-
pamil or digitalis) `' 22, 23) 
 The increase in ventricular response during 
atrial fibrillation through an accessory pathway 
in this patient may have the following expla-
nations. First, diltiazem may have shortened 
the conduction time and refractory period of the 
accessory pathway, an alternative favoured by 
the effect of previous procainamide which 
prevented this phenomenon. Secondly, dil-
tiazem, by blocking atrioventricular nodal 
conduction, may have prevented atrial fibrilla-
tion impulses travelling antegradely through the 
atrioventricular node with preferential use of the 
accessory pathway. Further detailed electrophy-
siological studies are needed to elucidate this 
case. Any drug which blocks at the atrioven-
tricular node and shortens the refractory period 
of the accessory pathway is potentially dan-
gerous and contraindicated in the Wolff-
Parkinson-White syndrome. 
 In conclusion our results suggest that in-
travenous diltiazem acts in a way similar to 
verapamil and shows the electrophysiological 
properties of a calcium antagonist and was well 
tolerated. Diltiazem may be useful for the acute 
treatment of paroxysmal supraventricular tach-
ycardia, atrial flutter and atrial fibrillation. 
However, diltiazem may be contraindicated in
atrial fibrillation associated with the Wolff-
Parkinson-White syndrome.
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